Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital

Context Therapeutics (NASDAQ:CNTX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $9.00 price target on the stock.

Other equities analysts have also recently issued reports about the company. Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. HC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st. Finally, JMP Securities began coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $6.17.

Context Therapeutics Price Performance

CNTX stock traded down $0.00 during midday trading on Wednesday, reaching $0.78. The company had a trading volume of 28,074 shares, compared to its average volume of 403,820. The firm has a 50-day moving average price of $0.77 and a 200-day moving average price of $1.26. The company has a market capitalization of $69.80 million, a P/E ratio of -0.86 and a beta of 2.18. Context Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, equities analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. State Street Corp raised its holdings in Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after buying an additional 19,800 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Context Therapeutics during the third quarter valued at about $89,000. Franklin Resources Inc. bought a new position in shares of Context Therapeutics during the third quarter valued at about $3,689,000. Clear Harbor Asset Management LLC boosted its holdings in shares of Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after purchasing an additional 21,804 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock worth $661,000 after purchasing an additional 52,830 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.